XTX Topco Ltd Invests $457,000 in Cogent Biosciences, Inc. (NASDAQ:COGT)

XTX Topco Ltd acquired a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 58,560 shares of the technology company's stock, valued at approximately $457,000. XTX Topco Ltd owned about 0.05% of Cogent Biosciences at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC raised its position in shares of Cogent Biosciences by 9.9% in the fourth quarter. Barclays PLC now owns 193,068 shares of the technology company's stock worth $1,506,000 after buying an additional 17,384 shares in the last quarter. Optimize Financial Inc bought a new stake in Cogent Biosciences during the fourth quarter valued at approximately $157,000. Renaissance Technologies LLC purchased a new position in Cogent Biosciences in the 4th quarter worth approximately $1,895,000. FMR LLC increased its holdings in shares of Cogent Biosciences by 99.2% in the 4th quarter. FMR LLC now owns 16,569,256 shares of the technology company's stock worth $129,240,000 after buying an additional 8,249,845 shares during the last quarter. Finally, Springhill Fund Asset Management HK Co Ltd purchased a new stake in shares of Cogent Biosciences during the 4th quarter valued at $4,279,000.

Cogent Biosciences Stock Performance

Shares of NASDAQ COGT traded up $0.13 during midday trading on Friday, hitting $4.64. 1,026,762 shares of the company traded hands, compared to its average volume of 1,261,383. Cogent Biosciences, Inc. has a 12-month low of $3.72 and a 12-month high of $12.61. The firm has a market cap of $528.26 million, a P/E ratio of -1.87 and a beta of 1.67. The stock has a 50-day moving average price of $6.10 and a 200 day moving average price of $8.20.

Analyst Ratings Changes

COGT has been the topic of a number of research analyst reports. Wedbush reissued a "neutral" rating and issued a $11.00 target price on shares of Cogent Biosciences in a research note on Tuesday, February 25th. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Robert W. Baird cut their target price on Cogent Biosciences from $10.00 to $8.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. HC Wainwright decreased their price target on shares of Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, January 14th. Finally, Piper Sandler raised shares of Cogent Biosciences to a "strong-buy" rating in a research note on Friday, March 7th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Cogent Biosciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.43.

Cogent Biosciences Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.